Plain-English translation of NCT07597772 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new imaging agent called SNA014 combined with a type of scan called PET/CT to help doctors see pancreatic cancer more clearly. The imaging agent is designed to attach to cancer cells and make them show up brighter on the scan, which could help doctors diagnose and monitor the disease more accurately.
Current imaging methods don't always show pancreatic cancer clearly enough. This trial is exploring whether this new medication can improve how well doctors can spot and track pancreatic cancer, which could lead to better treatment decisions.
You likely qualify if…
You likely don't qualify if…
You would receive an injection of the imaging medication followed by a PET/CT scan, which is a non-invasive imaging procedure where you lie still inside a scanner for a short period. This is a diagnostic trial with a small group of 12 patients, so the focus is on testing whether this new imaging method works well for detecting pancreatic cancer. The trial is currently recruiting patients.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
SmartNuclide Biopharma
Collaborators
Tianjin Medical University Cancer Institute and Hospital
Enrollment target
~12 participants
Started
October 2025
Primary completion
July 2026
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Dong Dai, Doctor
SmartNuclide Biopharma
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.